Menu
← Oncology Approval Tracker
FDA DECISION ·
Brukinsa tablets
zanubrutinib · BeOne Medicines USA
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A 160 mg tablet formulation for adults with mantle cell lymphoma after at least one prior therapy.
LAMPGEN ANALYSIS
Why it matters
The tablet presents the existing later-line mantle cell indication under a formulation-specific accelerated approval.
What research teams should watch
Confirm prior treatment and distinguish the scored tablet’s strength from the earlier 80 mg capsule.
PRIMARY RECORDS